NCT06844357View on ClinicalTrials.gov

A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

March 27, 2025

Primary Completion Date

April 1, 2029

Study Completion Date

April 1, 2029

Conditions
HCC
Interventions
DRUG

tirapazamine

Intra-arterial injection into the tumor feeding artery

PROCEDURE

Transarterial Embolization (TAE)

Lipiodol and Gelfoam used to embolize tumor vessels and induce tumor hypoxia

PROCEDURE

TACE

TACE with epirubicin

Trial Locations (2)

210009

RECRUITING

Zhongda Hospital, Affiliated to Southeast University, Nanjing

323000

RECRUITING

Lishui Central Hospital, Lishui

All Listed Sponsors
lead

Zhejiang Raygene Pharmaceuticals Co., Ltd

INDUSTRY